Paper Details

  1. Home
  2. Paper Details

Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes.

Author: HustedSteen, LiJianguo, StoreyRobert F, TangWeifeng, TengRenli

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study developed population pharmacokinetic models for ticagrelor and its metabolite, AR-C124910XX, in patients with acute coronary syndromes. Demographic and clinical factors were evaluated for their impact on the pharmacokinetics of both ticagrelor and AR-C124910XX.
Paper Details　
Original Abstract of the Article :
Ticagrelor is an orally administered antiplatelet agent used to reduce thrombotic events in patients with acute coronary syndromes. Data from two studies in patients with acute coronary syndromes with large amounts of pharmacokinetic (PK) data (phase IIb DISPERSE-2 study (n = 609)); phase III PLATO ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.5414/CP202549

データ提供：米国国立医学図書館（NLM）

Ticagrelor: Understanding its Journey Through the Body

Ticagrelor, an antiplatelet agent, plays a crucial role in preventing blood clots in patients with acute coronary syndromes. This research investigates the pharmacokinetics of ticagrelor, the study of how a drug moves through the body, in patients with acute coronary syndromes. The study utilizes data from two large clinical trials, DISPERSE-2 and PLATO, to develop a population pharmacokinetic model for ticagrelor and its metabolite, AR-C124910XX.

Unraveling the Pharmacokinetic Profile of Ticagrelor

The study reveals the impact of various demographic and clinical factors on the pharmacokinetics of ticagrelor and its metabolite. This information helps to optimize dosing strategies, ensuring that patients receive the appropriate amount of medication for optimal therapeutic effect and minimizing the risk of adverse effects.

Personalized Treatment Approaches

This research emphasizes the importance of personalized treatment approaches, considering individual patient factors to optimize drug dosage and minimize side effects. The study contributes to the development of more precise and effective treatment strategies for patients with acute coronary syndromes.

Dr.Camel's Conclusion

Just as a camel navigates the vast and diverse landscapes of the desert, researchers are constantly exploring the complex pathways of drug metabolism. This study provides a valuable map of ticagrelor's journey through the body, highlighting the importance of individualized treatment approaches for optimizing therapeutic outcomes. This research is a testament to the ongoing efforts to improve the lives of patients with cardiovascular disease and enhance their treatment experience.

Date :
  1. Date Completed 2017-01-10
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

27191766

DOI: Digital Object Identifier

10.5414/CP202549

Related Literature

Article Analysis
・Effects of ticagrelor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.